Associated Papers
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J et al.
Cancer Biology & Therapy, 2019
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.
Breccia M et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Select a paper to view details